Fundraising FoxTetraphase Pharmaceuticals
acquired by La Jolla Pharmaceutical CompanyWatertown, US · 6 known investors
Find your way into Tetraphase Pharmaceuticals
Sign up to find every way you can get introduced to Tetraphase Pharmaceuticals
- Your email: who you already know at Tetraphase Pharmaceuticals, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tetraphase Pharmaceuticals team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Acquired by La Jolla Pharmaceutical Company July 2020 · $43M ($43.0 million upfront cash plus up to $16.0 million in contingent value rights) · source ↗
Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.
Founders & leadership
Board
Investors · 6
How we know: F-Prime Capital's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$10M disclosed across 1 round · 2020
▶$10MraisedJan 2020 · 1 investors · PharmaceuticalsRule 506(b)
- L. Patrick GageDirector
- Keith MaherDirector
- Guy MacdonaldDirector
- Gerri HenwoodDirector
- Larry EdwardsExecutive Officer, Director
- Maria StahlExecutive Officer
- Christopher WattExecutive Officer
- Nancy J. WysenskiDirector
- Garen BohlinDirector
- Steven BoydDirector
- Jeffrey A. ChodakewitzDirector
- John G. FreundDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $700K
- Placement agents
- H.C. Wainwright & Co.
- First sale
- Jan 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Tetraphase Pharmaceuticals do?
- Tetraphase Pharmaceuticals was a Watertown, MA biopharmaceutical company developing novel tetracycline antibiotics, including its lead drug Xerava (eravacycline) for multidrug-resistant bacterial infections.
- Who are Tetraphase Pharmaceuticals's investors?
- Tetraphase Pharmaceuticals's investors include Bay City Capital, F-Prime Capital, Excel Venture Management, Flagship Ventures, Mediphase Venture Partners.
- How much funding has Tetraphase Pharmaceuticals raised?
- Tetraphase Pharmaceuticals has disclosed $10M raised across 1 round.
- Who acquired Tetraphase Pharmaceuticals?
- Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
- Where is Tetraphase Pharmaceuticals headquartered?
- Tetraphase Pharmaceuticals is headquartered in Watertown, US.